FDA Accepts Tasly's Master File for Stem Cell Products, Setting New Quality Benchmark

The U.S. Food and Drug Administration (FDA) has accepted Tasly Pharmaceutical Group's Device Master File (DMF) for its mesenchymal stem cell (MSC) platform, establishing what the company calls the first industry quality control standard for such therapies. The acceptance, confirmed on January 26, 2026, provides a regulatory reference for future MSC-based product filings. The DMF details critical quality standards for cell sourcing, manufacturing, and testing. This regulatory milestone could streamline the development pathway for Tasly's own MSC therapies and potentially serve as a template for other developers in the field, aiming to bring greater consistency to a rapidly evolving segment of regenerative medicine.